Fixed dose combination inhalers for COPD have been flagged as high growth prescription items for the Pharmaceutical Benefits Scheme. In its annual expenditure report, the PBS highlights the LABA/LAMA combo tiotropium/olodaterol (Spiolto Respimat) as one of the products with the highest growth in prescription volume, with numbers increasing by 760% from 9,985 to 85,840 scripts ...
Respiratory drugs highlighted in PBS costs report
By Michael Woodhead
18 Jan 2018